Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Company Growth (employees)
Summit, US
Size (employees)
7,132 (est)
Celgene Corporation was founded in 1986 and is headquartered in Summit, US

Key People at Celgene Corporation

Mark Alles

Mark Alles

Chief Executive Officer
Robert Hugin

Robert Hugin

Executive Chairman
Jacqualyn Fouse

Jacqualyn Fouse

President and Chief Operating Officer
Peter Kellogg

Peter Kellogg

Executive Vice President and Chief Financial Officer

Celgene Corporation Office Locations

Celgene Corporation has offices in Summit, Boudry and Singapore
Summit, US (HQ)
86 Morris Ave
Singapore, SG
200 Newton Rd
Boudry, CH
1 Route de Perreux

Celgene Corporation Data and Metrics

Celgene Corporation Financial Metrics

Celgene Corporation's revenue was reported to be $11.2 b in FY, 2016 which is a 21% increase from the previous period.

Revenue (FY, 2016)

11.2 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

10.8 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

2 b

EBIT (FY, 2016)

3.2 b

Market capitalization (15-Aug-2017)

106.6 b

Cash (31-Dec-2016)

6.2 b


101 b
Celgene Corporation's current market capitalization is $106.6 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


6.5 b7.7 b9.3 b11.2 b

Revenue growth, %


Cost of goods sold

340.4 m385.9 m420.1 m438 m

Gross profit

6.2 b7.3 b8.8 b10.8 b

Gross profit Margin, %


Operating expense total

4.7 b5.2 b7 b8.1 b


1.8 b2.5 b2.3 b3.2 b

EBIT margin, %


Interest expense

91.6 m176.1 m310.6 m500.1 m

Pre tax profit

1.7 b2.3 b2 b2.4 b

Income tax expense

215.5 m327.5 m421.5 m373.3 m

Net Income

1.4 b2 b1.6 b2 b
USDFY, 2013FY, 2014FY, 2015FY, 2016


3.2 b4.1 b4.9 b6.2 b


340.4 m393.1 m443.4 m497.9 m

Current Assets

7.6 b9.7 b9.4 b10.9 b


593.4 m642.6 m814.1 m929.8 m


2 b2.2 b4.9 b4.9 b

Total Assets

13.4 b17.3 b27.1 b28.1 b

Accounts Payable

156.2 m198.2 m240.8 m247.1 m

Total Debt

544.8 m605.9 m500.7 m

Current Liabilities

1.9 b2.1 b2 b3 b

Additional Paid-in Capital

8.7 b9.8 b11.1 b12.4 b

Retained Earnings

4.5 b6.5 b8.1 b10.1 b

Total Equity

5.6 b6.5 b5.9 b6.6 b

Debt to Equity Ratio

0.1 x0.1 x0.1 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

2.4 x2.7 x4.6 x4.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

1.4 b2 b1.6 b2 b

Accounts Receivable

(101.4 m)(166.3 m)(304.7 m)(222.4 m)


(89.7 m)(56.5 m)(50.6 m)(55.3 m)

Cash From Operating Activities

2.2 b2.8 b2.5 b4 b

Capital Expenditures

(119.7 m)(150.3 m)(286.3 m)(236.2 m)

Cash From Investing Activities

(528.6 m)(1.4 b)(6.3 b)(1 b)

Long-term Borrowings

(513.9 m)

Cash From Financing Activities

(553.7 m)(417.4 m)4.6 b(1.6 b)

Interest Paid

90.8 m196.2 m243.3 m527.2 m

Income Taxes Paid

291.9 m294.6 m361.1 m373 m

Free Cash Flow

2.3 b3 b2.8 b4.2 b
USDY, 2016


31.9 x


25.4 x


24 x


1.6 m


0.1 x

Financial Leverage

4.3 x

Celgene Corporation Operating Metrics

FY, 2016

Active Clinical Studies


    Celgene Corporation Market Value History

    Celgene Corporation Median Salaries

    Source: 55 public H-1B filings from Celgene Corporation

    Traffic Overview of Celgene Corporation

    Celgene Corporation Online and Social Media Presence

    Celgene Corporation Company Life and Culture

    You may also be interested in